Login to Your Account



ODAC Meeting Door Opener For New Prostate Cancer Drugs

By Mari Serebrov


Friday, September 16, 2011
Recognizing the unmet needs of patients with specific types of prostate cancer, the FDA may be opening the door for new drugs and surrogate endpoints.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription